GLP1R and type 2 diabetes mellitus: QW efpeglenatide significantly lowered HbA1c levels in patients with early-stage T2DM compared to placebo. Doses of 3 and 4 mg resulted in notable weight loss compared with the placebo group. The safety profile matched that of other GLP-1 RAs, with no neutralizing antibodies detected.